人参皂苷Rg3 PLGA纳米粒的处方优化及制备工艺研究  

Optimization of formulation and preparation of ginsenoside Rg3 PLGA nanoparticles

作　　者：潘翠珊 王风华[2] 郭家伟[1] 桑玮 王岩[1] 

机构地区：[1]广东药学院,广州510006 [2]中山大学肿瘤防治中心内科,广州510060

出　　处：《中南药学》2015年第11期1132-1136,共5页Central South Pharmacy

基　　金：广东省科技计划项目(No.2011B031800335);广东省教育厅学科建设专项资金(No.2013KJCX0110)

摘　　要：目的为了提高人参皂苷Rg3的生物利用度和靶向性,以聚乳酸-羟基乙酸共聚物(PLGA)为载体材料,研究人参皂苷Rg3 PLGA纳米粒的处方和制备工艺。方法采用纳米沉淀法制备纳米粒,HPLC测定人参皂苷Rg3的含量。以包封率为指标,采用单因素和正交试验法优选处方和工艺。结果人参皂苷Rg3 PLGA纳米粒的最佳处方和工艺条件为:PLGA浓度为10 mg·m L-1,人参皂苷Rg3浓度为3 mg·m L-1,有机相与水相体积比为1:3。制备的纳米粒平均粒径为186.1 nm,包封率为87.29%。结论该工艺方法简便、稳定可行,适用于人参皂苷Rg3 PLGA纳米粒的制备。Objective To improve the bioavailability and targeting property of ginsenoside Rg3 and to optimize prescription and preparation of ginsenoside Rg3 PLGA nanoparticles. Methods Nanoparticles were prepared by nanoprecipitation method, and the content of ginsenoside Rg3 was determined by HPLC. With the entrapment efficiency as the index, the prescription and process were optimized by single factor investigation and orthogonal test. Results The optimum prescription and conditions were as follows： the concentration of PLGA was 10 mg·mL^- 1; the concentration of Rg3 was 3 mg·mL^- 1; the ratio of organic phase and water phase was 1 ：3. The average particle size of nanoparticles was 186.1 nm, and the entrapment efficiency was 87.29%. Conclusion The craft is stable and feasibleapplicable for the preparation of ginsenoside Rg3 PLGA nanoparticles.

关 键 词：人参皂苷RG3 纳米粒 制备工艺 正交试验设计 

分 类 号：R283[医药卫生—中药学]